STOK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
STOK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Stoke Therapeutics's annualized ROCE % for the quarter that ended in Sep. 2023 was -48.44%.
The historical data trend for Stoke Therapeutics's ROCE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stoke Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:
ROCE % | = | EBIT | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(A: Dec. 2022 ) | (A: Dec. 2021 ) | (A: Dec. 2022 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(A: Dec. 2022 ) | (A: Dec. 2021 ) | (A: Dec. 2022 ) | |||||
= | -104.356 | / | ( ( (238.865 - 17.139) | + | (256.067 - 31.394) ) | / 2 ) | |
= | -104.356 | / | ( (221.726 | + | 224.673) | / 2 ) | |
= | -104.356 | / | 223.1995 | ||||
= | -46.75 % |
Stoke Therapeutics's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:
ROCE % | = | EBIT (1) | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(Q: Sep. 2023 ) | (Q: Jun. 2023 ) | (Q: Sep. 2023 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(Q: Sep. 2023 ) | (Q: Jun. 2023 ) | (Q: Sep. 2023 ) | |||||
= | -108.936 | / | ( ( (256.919 - 21.837) | + | (239.889 - 25.201) ) | / 2 ) | |
= | -108.936 | / | ( ( 235.082 | + | 214.688 ) | / 2 ) | |
= | -108.936 | / | 224.885 | ||||
= | -48.44 % |
(1) Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stoke Therapeutics (NAS:STOK) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Thank you for viewing the detailed overview of Stoke Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Barry Ticho | officer: Chief Medical Officer | C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730 |
Ian F Smith | director | C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Jonathan Allan | officer: General Counsel & Corp Sec | C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730 |
Huw M. Nash | officer: COO & CBO | C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730 |
Atp Life Science Ventures, L.p. | 10 percent owner | 230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169 |
Atp Iii Gp, Ltd. | 10 percent owner | 230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169 |
Skorpios Trust | 10 percent owner | 195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030 |
Montrago Trustees Ltd | 10 percent owner | 195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030 |
Blue Horizon Enterprise Ltd | 10 percent owner | 3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110 |
Ezbon International Ltd | 10 percent owner | 3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110 |
Gene Liau | officer: EVP Research & Preclinical Dev | C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730 |
Arthur A Levin | director | 1896 RUTHERFORD ROAD, CARLSBAD CA 92008 |
Stephen J Tulipano | officer: CFO | C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140 |
Arthur Tzianabos | director | C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730 |
Kaye Edward M. Md | director, officer: CEO | 3450 MONTE VILLA PARKWAY, BOTHELL WA 98011 |
From GuruFocus
By Business Wire 11-29-2022
By PRNewswire 10-18-2022
By Business Wire 02-07-2023
By Business Wire 04-25-2023
By Business Wire 06-16-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.